These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 15203261

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada.
    Casciano R, Tarride JE, Breton MC, Stern L, Langer A.
    Can J Clin Pharmacol; 2004; 11(1):e179-90. PubMed ID: 15300960
    [Abstract] [Full Text] [Related]

  • 3. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA, Casciano R, Stern L, Rejas J.
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [Abstract] [Full Text] [Related]

  • 4. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
    Buller N, Gillen D, Casciano R, Doyle J, Wilson K.
    Pharmacoeconomics; 2003 Oct; 21 Suppl 1():25-32. PubMed ID: 12648032
    [Abstract] [Full Text] [Related]

  • 5. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP, Szucs TD.
    Med Klin (Munich); 2004 Sep 15; 99(9):500-5. PubMed ID: 15372179
    [Abstract] [Full Text] [Related]

  • 6. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
    Circulation; 2004 Jul 27; 110(4):386-91. PubMed ID: 15262833
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Jul 27; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT investigators.
    Eur J Cardiovasc Prev Rehabil; 2005 Feb 27; 12(1):29-36. PubMed ID: 15703503
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
    Schwartz GG, Ganz P, Waters D, Arikian S.
    Am J Cardiol; 2003 Nov 01; 92(9):1109-12. PubMed ID: 14583367
    [Abstract] [Full Text] [Related]

  • 10. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M, O'donnell J, Olsson A.
    Int J Cardiol; 2005 Oct 10; 104(3):251-6. PubMed ID: 16186052
    [Abstract] [Full Text] [Related]

  • 11. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E.
    J Am Coll Cardiol; 2008 Sep 09; 52(11):914-20. PubMed ID: 18772061
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J, Lindgren P, Spiesser J, Parry D, Jönsson B.
    Clin Ther; 2007 Jun 09; 29(6):1184-202. PubMed ID: 17692733
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Jun 09; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 14. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A.
    Eur Heart J; 2005 May 09; 26(9):890-6. PubMed ID: 15764620
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun 09; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
    Taylor DC, Pandya A, Thompson D, Chu P, Graff J, Shepherd J, Wenger N, Greten H, Carmena R, Drummond M, Weinstein MC.
    Eur J Health Econ; 2009 Jul 09; 10(3):255-65. PubMed ID: 18800232
    [Abstract] [Full Text] [Related]

  • 17. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T, Akar Bayram N, Kayhan T, Canbay A, Sahin D, Durmaz T, Ozdemir O, Aydoğdu S, Diker E.
    Anadolu Kardiyol Derg; 2008 Dec 09; 8(6):407-12. PubMed ID: 19103535
    [Abstract] [Full Text] [Related]

  • 18. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR, Incremental DEcrease through Aggressive Lipid Lowering Investigators.
    Am J Cardiol; 2009 Mar 01; 103(5):577-82. PubMed ID: 19231315
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.
    Am J Manag Care; 2006 Nov 01; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [Abstract] [Full Text] [Related]

  • 20. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG.
    Am J Cardiol; 1998 Mar 01; 81(5):578-81. PubMed ID: 9514453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.